The new appointment will take Repositive to the next level of scaling commercial activities with a new core offering for the biopharmaceutical market, ensuring a high value proposition for current and future customers. Simultaneously, Repositive continues work connecting biopharmaceutical companies with the right preclinical models. Repositive's mission is to accelerate the development of cancer drugs by connecting biopharma quickly and efficiently to the right pre-clinical model.
December 2020, Cambridge –Repositive, a Cambridge-based start-up connecting biopharma researchers with the right preclinical cancer models and CRO partners, has today announced a change in leadership with the appointment of Catherine McDermott as the new Chief Executive Officer. Fiona Nielsen, the company co-founder, will pass on leadership of the company to Catherine and will remain with Repositive in a support capacity until February 2021.
“Repositive has made real progress towards enabling the secure discovery and sharing of data through the development of our Repositive cancer models platform and concierge service. Our Cancer Models repository has grown to become the largest global online resource for preclinical cancer models, with a wide reach established across the oncology research community. We are now seeing a surge in interest for our services and we are confident in Catherine’s ability as CEO to drive the long–term performance of Repositive by developing our customer offering.” - Fiona Nielsen, Founder and outgoing CEO of Repositive
Catherine has a strong commercial background in healthcare/pharma strategy and scaling efficient operations, having worked across a wide range of organisations in various leadership positions, including Chief Digital Officer at McKesson and Operations Director at Circle Health. This summer, she also led the Covid19 response for NHS Property Services. During her time at McKesson, Catherine re-positioned the UK digital businesses to accelerate growth and worked with pharmaceutical companies to develop services to increase drug reach and efficacy. Catherine’s extensive experience in successfully designing and delivering world class business change programmes and customer focused improvements will support the development of Repositive’s core offering. This will enable further growth of the business and bring Repositive closer to the ultimate goal of aiding the biopharmaceutical to source preclinical models and improving the success of drug discovery.
“I think Repositive has a great product and I am excited to be joining the business at this time. I have a great appreciation and respect for all of Fiona’s contributions over her many years of dedication at the company. I will be taking over Repositive on solid foundations thanks to the work of Fiona and the team. My focus is to grow the business by continually finding better and faster ways for customers to find the right pre-clinical models. Our cancer model’s platform has the world’s biggest range of models and our cancer model scout service will find the best models available, even for rare searches. Repositive is based on the concept of social enterprise, which means we have a clear aim to make a difference: every action we take is intended to bring us closer to accelerating the drug discovery process and bringing new treatments and cures to patients.” - Catherine McDermott, newly appointed CEO
Repositive has a track record of advancing preclinical oncology research via their Cancer Model Scout service and global network of preclinical cancer model CROs. This service involves conducting a comprehensive model search based on a well-defined scope of client needs, with results delivered within 2-4 weeks in a data-rich report of all identified matching models across CROs in their network.
The team will continue to ensure the highest quality of service and a customer centric approach under newly appointed CEO, Catherine McDermott. In order to scale up commercial operations and continue to open new opportunities for Repositive’s service solutions, the company are working to expand collaborations with both biopharma customers and CRO partners. With Catherine’s knowledge of the industry and a remarkable track record of driving commercial growth, the Repositive leadership team are confident that this change will bring value to the company’s current and future customers.